Spots Global Cancer Trial Database for therapeutic tumor infiltrating lymphocytes
Every month we try and update this database with for therapeutic tumor infiltrating lymphocytes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00045149 | Melanoma (Skin) | aldesleukin therapeutic tum... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | NCT00062036 | Melanoma (Skin) | aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | NCT00019084 | Breast Cancer Cervical Cancer Colorectal Canc... Lung Cancer Ovarian Cancer Pancreatic Canc... | aldesleukin mutant p53 pept... ras peptide can... sargramostim therapeutic aut... therapeutic tum... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy | NCT00019357 | Unspecified Adu... | aldesleukin therapeutic aut... therapeutic tum... | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma | NCT00002535 | Melanoma (Skin) | aldesleukin lymphokine-acti... therapeutic tum... cyclophosphamid... indomethacin | 17 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Metastatic Cancer | NCT00002733 | Kidney Cancer Melanoma (Skin) Unspecified Adu... | aldesleukin recombinant int... therapeutic tum... cimetidine | 18 Years - | Hoag Memorial Hospital Presbyterian | |
| Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | NCT01807182 | Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Metastatic Mela... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Therapeutic Tum... | 18 Years - | Fred Hutchinson Cancer Center | |
| Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung | NCT00301730 | Breast Cancer Metastatic Canc... | aldesleukin therapeutic tum... trastuzumab paclitaxel conventional su... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | NCT00062036 | Melanoma (Skin) | aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Biological Therapy in Treating Patients With Metastatic Cancer | NCT00002733 | Kidney Cancer Melanoma (Skin) Unspecified Adu... | aldesleukin recombinant int... therapeutic tum... cimetidine | 18 Years - | Hoag Memorial Hospital Presbyterian | |
| Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00096382 | Melanoma (Skin) | aldesleukin filgrastim therapeutic tum... cyclophosphamid... fludarabine pho... radiation thera... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma | NCT00002535 | Melanoma (Skin) | aldesleukin lymphokine-acti... therapeutic tum... cyclophosphamid... indomethacin | 17 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage IV Melanoma | NCT00003665 | Melanoma (Skin) | dendritic cell-... gp100 antigen therapeutic tum... tyrosinase pept... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00045149 | Melanoma (Skin) | aldesleukin therapeutic tum... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00085462 | Melanoma (Skin) | aldesleukin filgrastim gp100-fowlpox v... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma | NCT00046852 | Infection Multiple Myelom... | filgrastim pneumococcal po... therapeutic aut... therapeutic tum... carmustine cyclophosphamid... melphalan bone marrow abl... peripheral bloo... | 18 Years - 80 Years | University of Maryland, Baltimore | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00006113 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen recombinant CD4... recombinant int... recombinant int... sargramostim therapeutic aut... therapeutic tum... tyrosinase pept... Candida albican... | 18 Years - | University of Southern California | |
| Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00085462 | Melanoma (Skin) | aldesleukin filgrastim gp100-fowlpox v... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy | NCT00019357 | Unspecified Adu... | aldesleukin therapeutic aut... therapeutic tum... | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | NCT02500576 | Metastatic Mela... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Pembrolizumab Quality-of-Life... Therapeutic Tum... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
